Biomarkers for diagnosis and prediction of therapy responses in allergic diseases and asthma.
- Breiteneder H Institute of Pathophysiology and Allergy Research, Medical University of Vienna, Vienna, Austria.
- Peng YQ Swiss Institute of Allergy and Asthma Research (SIAF), University Zurich, Davos, Switzerland.
- Agache I Department of Allergy and Clinical Immunology, Faculty of Medicine, Transylvania University of Brasov, Brasov, Romania.
- Diamant Z Department of Respiratory Medicine & Allergology, Institute for Clinical Science, Skane University Hospital, Lund University, Lund, Sweden.
- Eiwegger T Translational Medicine Program, Research Institute, Hospital for Sick Children, Toronto, ON, Canada.
- Fokkens WJ Department of Otorhinolaryngology, Amsterdam University Medical Centres, Amsterdam, The Netherlands.
- Traidl-Hoffmann C CK CARE, Christine Kühne Center for Allergy Research and Education, Davos, Switzerland.
- Nadeau K Sean N. Parker Center for Allergy & Asthma Research, Stanford University, Stanford, CA, USA.
- O'Hehir RE Department of Allergy, immunology and Respiratory Medicine, Central Clinical School, Monash University, Melbourne, Vic., Australia.
- O'Mahony L Departments of Medicine and Microbiology, APC Microbiome Ireland, National University of Ireland, Cork, Ireland.
- Pfaar O Department of Otorhinolaryngology, Head and Neck Surgery, Section of Rhinology and Allergy, University Hospital Marburg, Philipps-Universität Marburg, Marburg, Germany.
- Torres MJ Allergy Unit, Regional University Hospital of Malaga-IBIMA-UMA-ARADyAL, Malaga, Spain.
- Wang DY Department of Otolaryngology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
- Zhang L Department of Otolaryngology Head and Neck Surgery and Department of Allergy, Beijing TongRen Hospital, Beijing, China.
- Akdis CA Swiss Institute of Allergy and Asthma Research (SIAF), University Zurich, Davos, Switzerland.
- 2020-09-07
Published in:
- Allergy. - 2020
English
Modern health care requires a proactive and individualized response to diseases, combining precision diagnosis and personalized treatment. Accordingly, the approach to patients with allergic diseases encompasses novel developments in the area of personalized medicine, disease phenotyping and endotyping, and the development and application of reliable biomarkers. A detailed clinical history and physical examination followed by the detection of IgE immunoreactivity against specific allergens still represents the state of the art. However, nowadays, further emphasis focuses on the optimization of diagnostic and therapeutic standards and a large number of studies have been investigating the biomarkers of allergic diseases, including asthma, atopic dermatitis, allergic rhinitis, food allergy, urticaria and anaphylaxis. Various biomarkers have been developed by omics technologies, some of which lead to a better classification of distinct phenotypes or endotypes. The introduction of biologicals to clinical practice increases the need for biomarkers for patient selection, prediction of outcomes and monitoring, to allow for an adequate choice of the duration of these costly and long-lasting therapies. Escalating healthcare costs together with questions about the efficacy of the current management of allergic diseases require further development of a biomarker-driven approach. Here, we review biomarkers in diagnosis and treatment of asthma, atopic dermatitis, allergic rhinitis, viral infections, chronic rhinosinusitis, food allergy, drug hypersensitivity and allergen immunotherapy with a special emphasis on specific IgE, the microbiome and the epithelial barrier. In addition, EAACI guidelines on biologicals are discussed within the perspective of biomarkers.
- Language
-
- English
- Open access status
- hybrid
- Identifiers
-
- DOI 10.1111/all.14582
- PMID 32893900
- Persistent URL
- https://folia.unifr.ch/global/documents/41571
Statistics
Document views: 7
File downloads:
- fulltext.pdf: 0